The Conversation (0)
Bioresearch online reported that Tekmira Pharmaceuticals (TSX:TKM,NASDAQ:TKMR) has been awarded a $140 million contract by the U.S. Department of Defense for the research of a treatment for the Ebola virus. According to Bioresearch, Tekmira has seen dramatic progress in human trials for TKM-Ebola that started last month.
As quoted in the publication
The global market for Ebola is small, because the disease is rare. According to the International Business Times, Ebola has affected fewer than 10,000. Because it’s a relatively limited market, pharmaceutical companies are less willing to fund the difficult and lengthy research process that often goes into developing treatments for more common diseases, like malaria. However, this is not to understate the severity of the virus.
Click here to read the full Bioresearch Online Article.
Click here to see the Tekmira Pharmaceuticals Corporation (TSX:TKM,NASDAQ:TKMR) profile.